2022 Rome Action Plan on Paediatric HIV & TB
All partners commit to:
163. Address inequities by tackling the stigma and discrimination in communities, schools, and healthcare settings that prevent children living with HIV from accessing testing and treatment.
164. Increase literacy about CD4 testing and viral load and promote a client-centred approach to support expansion of access to viral load for pregnant and breastfeeding women and children on treatment, including at the point-of-care.
165. Review and assess emerging co-infections for immunocompromised infants and children, including those with advanced HIV disease, such as severe bacterial infections, fungal infections, and others for country consideration and implementation.
166. Engage affected communities for input and guidance on investment and programmatic priorities, provide support to in-country civil society organizations to engage in advocacy and demand creation for new tools, and ensure data is publicly available to support communities and civil society to monitor progress regarding uptake and implementation of essential diagnostic tools.
MPP commits to:
316. Continue to facilitate access to the best available medicines for children. Specifically, the MPP will continue to work with patent holders to in-license paediatric drugs as prioritized by the WHO/PADO, and to sublicense to generic manufacturers to ensure that appropriate formulations are rapidly developed, registered and made available in as many developing countries as possible.
317. Continue to inform all countries in the paediatric license group on the status of paediatric ARV patents.
318. Expand its quarterly reported information on the progress of priority paediatric drug formulations, sharing not only the list of countries with regulatory filings, regulatory approvals, and supplies of paediatric DTG (10 mg scored dispersible tablets), but also reporting for paediatric ALD (ABC/3TC/DTG 60/30/5 mg) as an important upcoming addition to the paediatric HIV treatment toolbox. In addition, this reporting will include anonymized regulatory filing plans and timelines, as well as quarterly country-by-country volumes of medicines supplied across all countries covered by the MPP-ViiV Healthcare licence for paediatric DTG.